DaVita: After A 25% Drop, The Buyback Machine Is Cheap Again (NYSE:DVA)

seekingalpha.com · 2026-10-09

DaVita Inc. is rated a Buy with a $220 12-month price target, offering 22% upside from current levels. Read more on DVA stock here.

TickrTrends take: DaVita's recent 25% price decline has brought its valuation metrics into territory that may attract value-oriented investors, aligning with TickrTrends' current undervalued assessment within the Healthcare sector. The company's buyback activity historically signals management confidence in pricing, and a cheaper stock price combined with share repurchases could influence earnings per share dynamics that warrant monitoring. Valuation-focused readers should track whether the company maintains its capital allocation strategy at these lower levels and how that affects shareholder returns relative to sector peers.

Read the full story at seekingalpha.com →